ARS Pharmaceuticals (SPRY) News Today → A once-in-a-century investment opportunity (From Stansberry Research) (Ad) Free SPRY Stock Alerts $9.03 -0.07 (-0.77%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 12:59 PM | insidertrades.comRichard E. Lowenthal Sells 5,147 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockMay 16 at 9:48 PM | marketbeat.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells 5,147 Shares of StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) CEO Richard E. Lowenthal sold 5,147 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $9.05, for a total value of $46,580.35. Following the completion of the transaction, the chief executive officer now directly owns 1,642,193 shares of the company's stock, valued at $14,861,846.65. The sale was disclosed in a filing with the SEC, which is available through this link.May 13, 2024 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Forecasted to Earn FY2027 Earnings of $0.60 Per ShareMay 13, 2024 | finance.yahoo.comARS Pharmaceuticals Inc (SPRY) Q1 2024 Earnings: Aligns with EPS Projections Amidst Regulatory ...May 11, 2024 | finance.yahoo.comARS Pharmaceuticals First Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.16 loss in 1Q 2023)May 11, 2024 | americanbankingnews.comSarina Tanimoto Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockMay 10, 2024 | insidertrades.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of StockMay 9, 2024 | investorplace.comSPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024May 9, 2024 | globenewswire.comARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | nasdaq.comARS Pharmaceuticals, Inc. Common Stock (SPRY) Insider ActivityMay 3, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Decreased by Levin Capital Strategies L.P.Levin Capital Strategies L.P. lowered its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 61.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 52,250 shares of the company's stock after selliMay 1, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Up 7.5%ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 7.5%April 30, 2024 | finance.yahoo.comARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandApril 30, 2024 | globenewswire.comARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandApril 26, 2024 | msn.comInsider Trading: ARS Pharmaceuticals’ (NASDAQ:SPRY) Insiders Buy Shares Worth $679KApril 19, 2024 | investing.comArs Pharmaceuticals CEO sells over $928k in company stockApril 18, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 3.4% Following Insider SellingARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 3.4% Following Insider SellingApril 18, 2024 | insidertrades.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 100,000 SharesApril 13, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Short Interest UpdateARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 5,500,000 shares, an increase of 29.4% from the March 15th total of 4,250,000 shares. Currently, 13.1% of the company's stock are short sold. Based on an average daily trading volume, of 643,600 shares, the days-to-cover ratio is presently 8.5 days.April 12, 2024 | investing.comArs Pharmaceuticals CEO sells shares worth over $927kApril 12, 2024 | investing.comArs pharmaceuticals exec sells shares worth over $927kApril 11, 2024 | insidertrades.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Richard E. Lowenthal Sells 100,000 SharesApril 9, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 6.8% ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 6.8%April 5, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 4.1%ARS Pharmaceuticals (NASDAQ:SPRY) Trading 4.1% HigherApril 3, 2024 | markets.businessinsider.comARS Pharma Submits Addl. Data In Response To FDA's CRL For NeffyApril 3, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn SituationApril 3, 2024 | globenewswire.comARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)April 1, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 6.1%ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 6.1%March 31, 2024 | 247wallst.comHuge Insider Buying From Buffett, an NFL Team Owner, a New CEOMarch 28, 2024 | insidertrades.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Purchases $3,964,656.00 in StockMarch 27, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Ra Capital Management, L.P. Buys 437,600 SharesARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) Director Ra Capital Management, L.P. purchased 437,600 shares of the company's stock in a transaction that occurred on Monday, March 25th. The shares were purchased at an average price of $9.06 per share, for a total transaction of $3,964,656.00. Following the completion of the transaction, the director now directly owns 8,994,374 shares of the company's stock, valued at $81,489,028.44. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.March 27, 2024 | insidertrades.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $21,133.86 in StockMarch 26, 2024 | marketbeat.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 2,343 Shares of StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) insider Sarina Tanimoto sold 2,343 shares of the firm's stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $9.02, for a total value of $21,133.86. Following the completion of the sale, the insider now directly owns 1,745,082 shares of the company's stock, valued at $15,740,639.64. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.March 26, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 1-Year High at $9.75ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week High at $9.75March 25, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Sees Large Volume IncreaseARS Pharmaceuticals (NASDAQ:SPRY) Sees Large Volume IncreaseMarch 25, 2024 | markets.businessinsider.comBuy Rating on ARS Pharmaceuticals Amid Strong neffy Approval Prospects and Indication ExpansionMarch 22, 2024 | insidertrades.comRichard E. Lowenthal Sells 1,918 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) StockMarch 21, 2024 | marketbeat.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells 1,918 Shares of StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) CEO Richard E. Lowenthal sold 1,918 shares of the company's stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $9.03, for a total transaction of $17,319.54. Following the completion of the transaction, the chief executive officer now directly owns 1,746,471 shares of the company's stock, valued at approximately $15,770,633.13. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.March 21, 2024 | finance.yahoo.comARS Pharmaceuticals Inc (SPRY) Reports Full Year and Q4 2023 Financial ResultsMarch 21, 2024 | globenewswire.comARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 19, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 4.9%ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 4.9%March 16, 2024 | insidertrades.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells $25,200.00 in StockMarch 15, 2024 | marketbeat.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells 2,800 Shares of StockARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) CEO Richard E. Lowenthal sold 2,800 shares of ARS Pharmaceuticals stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $9.00, for a total transaction of $25,200.00. Following the sale, the chief executive officer now directly owns 1,744,994 shares of the company's stock, valued at approximately $15,704,946. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.March 11, 2024 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Rating Reiterated by WedbushWedbush restated an "outperform" rating and set a $19.00 price target on shares of ARS Pharmaceuticals in a research note on Monday.March 10, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Fmr LLCFmr LLC lessened its holdings in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 72.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,307,340 shares of the company's stockMarch 7, 2024 | globenewswire.comARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor DayMarch 7, 2024 | marketbeat.comARS Pharmaceuticals, Inc. to Post FY2023 Earnings of ($0.61) Per Share, Leerink Partnrs Forecasts (NASDAQ:SPRY)ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2023 earnings per share estimates for shares of ARS Pharmaceuticals in a report issued on Tuesday, March 5th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($0.61) peMarch 6, 2024 | realmoney.thestreet.comARS Pharmaceuticals just upgraded at Leerink, here's whyMarch 6, 2024 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by RA Capital Management L.P.RA Capital Management L.P. raised its stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 214.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,459,678 shares of the company's stock after purchasingMarch 6, 2024 | globenewswire.comARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024 Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. SPRY Media Mentions By Week SPRY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼0.190.52▲Average Medical News Sentiment SPRY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼122▲SPRY Articles Average Week Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ABVX News Today IMNM News Today PLRX News Today ETNB News Today OPK News Today CNTA News Today ZNTL News Today DNTH News Today LQDA News Today TNGX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRY) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWhat’s Really Next for America…Porter & CompanyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
